Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 337 entries
Sorted by: Best Match Show Resources per page
Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case.

Case reports in hematology

Regragui S, Amelal S, Astati S, Zine M, Alami Drideb N, Al Bouzidi A, Messaoudi N, Benkirane M, Doghmi K, Mikdame M.
PMID: 22953078
Case Rep Hematol. 2012;2012:806476. doi: 10.1155/2012/806476. Epub 2012 May 07.

The thrombotic microangiopathy is a syndrome characterized by the combination of mechanical hemolytic anemia, peripheral thrombocytopenia, and organ failure of variable severity. In addition to the idiopathic form, several cases are identified as secondary to pregnancy, infections, disease systems,...

Cite
Regragui S, Amelal S, Astati S, et al. Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case Rep Hematol. 2012;2012:806476doi: 10.1155/2012/806476.
Regragui, S., Amelal, S., Astati, S., Zine, M., Alami Drideb, N., Al Bouzidi, A., Messaoudi, N., Benkirane, M., Doghmi, K., & Mikdame, M. (2012). Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case reports in hematology, 2012806476. https://doi.org/10.1155/2012/806476
Regragui, S, et al. "Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case." Case reports in hematology vol. 2012 (2012): 806476. doi: https://doi.org/10.1155/2012/806476
Regragui S, Amelal S, Astati S, Zine M, Alami Drideb N, Al Bouzidi A, Messaoudi N, Benkirane M, Doghmi K, Mikdame M. Thrombotic microangiopathy with skin localization secondary to cytarabine-daunorubicin association: report of a case. Case Rep Hematol. 2012;2012:806476. doi: 10.1155/2012/806476. Epub 2012 May 07. PMID: 22953078; PMCID: PMC3420723.
Copy Download .nbib Format: NLM
Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines.

American journal of blood research

Brandwein JM, Zhu N, Kumar R, Leber B, Sabloff M, Sandhu I, Kassis J, Olney HJ, Elemary M, Schuh AC.
PMID: 28804680
Am J Blood Res. 2017 Jul 25;7(4):30-40. eCollection 2017.

The treatment of acute myeloid leukemia (AML) in older patients is undergoing rapid changes, with a number of important publications in the past five years. Because of this, a group of Canadian leukemia experts has produced an update to...

Cite
Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res. 2017;7(4):30-40
Brandwein, J. M., Zhu, N., Kumar, R., Leber, B., Sabloff, M., Sandhu, I., Kassis, J., Olney, H. J., Elemary, M., & Schuh, A. C. (2017). Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. American journal of blood research, 7(4), 30-40.
Brandwein, Joseph M, et al. "Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines." American journal of blood research vol. 7,4 (2017): 30-40.
Brandwein JM, Zhu N, Kumar R, Leber B, Sabloff M, Sandhu I, Kassis J, Olney HJ, Elemary M, Schuh AC. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res. 2017 Jul 25;7(4):30-40. eCollection 2017. PMID: 28804680; PMCID: PMC5545212.
Copy Download .nbib Format: NLM
3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression.

Experimental and therapeutic medicine

Guo J, Zhao C, Yao R, Sui A, Sun L, Liu X, Wu S, Su Z, Li T, Liu S, Gao Y, Liu J, Feng X, Wang W, Zhao H, Cui Z, Li G, Meng F.
PMID: 30783426
Exp Ther Med. 2019 Mar;17(3):1593-1600. doi: 10.3892/etm.2019.7153. Epub 2019 Jan 04.

Three dimensional (3D) culture has gradually become a research hotspot in the field of drug screening, stem cell research, and tissue engineering due to its more physiological-like morphology and function. In this study, we compared the differences of cell...

Cite
Guo J, Zhao C, Yao R, et al. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Exp Ther Med. 2019;17(3):1593-1600doi: 10.3892/etm.2019.7153.
Guo, J., Zhao, C., Yao, R., Sui, A., Sun, L., Liu, X., Wu, S., Su, Z., Li, T., Liu, S., Gao, Y., Liu, J., Feng, X., Wang, W., Zhao, H., Cui, Z., Li, G., & Meng, F. (2019). 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Experimental and therapeutic medicine, 17(3), 1593-1600. https://doi.org/10.3892/etm.2019.7153
Guo, Jun, et al. "3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression." Experimental and therapeutic medicine vol. 17,3 (2019): 1593-1600. doi: https://doi.org/10.3892/etm.2019.7153
Guo J, Zhao C, Yao R, Sui A, Sun L, Liu X, Wu S, Su Z, Li T, Liu S, Gao Y, Liu J, Feng X, Wang W, Zhao H, Cui Z, Li G, Meng F. 3D culture enhances chemoresistance of ALL Jurkat cell line by increasing DDR1 expression. Exp Ther Med. 2019 Mar;17(3):1593-1600. doi: 10.3892/etm.2019.7153. Epub 2019 Jan 04. PMID: 30783426; PMCID: PMC6364197.
Copy Download .nbib Format: NLM
The role of targeted therapy in the management of patients with AML.

Blood advances

Perl AE.
PMID: 29296877
Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829. eCollection 2017 Nov 14.

Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration's approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent...

Cite
Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017;1(24):2281-2294doi: 10.1182/bloodadvances.2017009829.
Perl, A. E. (2017). The role of targeted therapy in the management of patients with AML. Blood advances, 1(24), 2281-2294. https://doi.org/10.1182/bloodadvances.2017009829
Perl, Alexander E. "The role of targeted therapy in the management of patients with AML." Blood advances vol. 1,24 (2017): 2281-2294. doi: https://doi.org/10.1182/bloodadvances.2017009829
Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017 Nov 14;1(24):2281-2294. doi: 10.1182/bloodadvances.2017009829. eCollection 2017 Nov 14. PMID: 29296877; PMCID: PMC5737125.
Copy Download .nbib Format: NLM
Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer.

Genome announcements

Tetz G, Tetz V.
PMID: 27491975
Genome Announc. 2016 Aug 04;4(4). doi: 10.1128/genomeA.00786-16.

We report here the complete genome sequence of the spore-forming Bacillus sp. strain VT 712 isolated from the duodenum of a patient with intestinal cancer. The genome is 3,921,583 bp, with 37.9% G+C content. It contains 3,768 predicted protein-coding...

Cite
Tetz G, Tetz V. Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer. Genome Announc. 2016;4(4)doi: 10.1128/genomeA.00786-16.
Tetz, G., & Tetz, V. (2016). Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer. Genome announcements, 4(4), . https://doi.org/10.1128/genomeA.00786-16
Tetz, George, and Tetz, Victor. "Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer." Genome announcements vol. 4,4 (2016). doi: https://doi.org/10.1128/genomeA.00786-16
Tetz G, Tetz V. Complete Genome Sequence of a Novel Bacillus sp. VT 712 Strain Isolated from the Duodenum of a Patient with Intestinal Cancer. Genome Announc. 2016 Aug 04;4(4). doi: 10.1128/genomeA.00786-16. PMID: 27491975; PMCID: PMC4974327.
Copy Download .nbib Format: NLM
Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles.

Chemistry Central journal

Ahmad N, Ahmad R, Alam MA, Ahmad FJ.
PMID: 29796830
Chem Cent J. 2018 May 23;12(1):65. doi: 10.1186/s13065-018-0434-1.

BACKGROUND: Doxorubicin hydrochloride (DOX·HCl), an anthracycline glycoside antibiotic, exhibits low oral bioavailability due to active efflux from intestinal P-glycoprotein receptors. The oral administration of DOX remains a challenge hence; no oral formulation for DOX is marketed, till date.AIM OF...

Cite
Ahmad N, Ahmad R, Alam MA, et al. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem Cent J. 2018;12(1):65doi: 10.1186/s13065-018-0434-1.
Ahmad, N., Ahmad, R., Alam, M. A., & Ahmad, F. J. (2018). Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chemistry Central journal, 12(1), 65. https://doi.org/10.1186/s13065-018-0434-1
Ahmad, Niyaz, et al. "Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles." Chemistry Central journal vol. 12,1 (2018): 65. doi: https://doi.org/10.1186/s13065-018-0434-1
Ahmad N, Ahmad R, Alam MA, Ahmad FJ. Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles. Chem Cent J. 2018 May 23;12(1):65. doi: 10.1186/s13065-018-0434-1. PMID: 29796830; PMCID: PMC5966352.
Copy Download .nbib Format: NLM
Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways.

Oncotarget

Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM.
PMID: 29435104
Oncotarget. 2017 Dec 31;9(4):4301-4317. doi: 10.18632/oncotarget.23794. eCollection 2018 Jan 12.

CREB (cAMP Response Element Binding protein) is a transcription factor that is overexpressed in primary acute myeloid leukemia (AML) cells and associated with a decreased event-free survival and increased risk of relapse. We recently reported a small molecule inhibitor...

Cite
Chae HD, Cox N, Dahl GV, et al. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017;9(4):4301-4317doi: 10.18632/oncotarget.23794.
Chae, H. D., Cox, N., Dahl, G. V., Lacayo, N. J., Davis, K. L., Capolicchio, S., Smith, M., & Sakamoto, K. M. (2018). Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget, 9(4), 4301-4317. https://doi.org/10.18632/oncotarget.23794
Chae, Hee-Don, et al. "Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways." Oncotarget vol. 9,4 (2018): 4301-4317. doi: https://doi.org/10.18632/oncotarget.23794
Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017 Dec 31;9(4):4301-4317. doi: 10.18632/oncotarget.23794. eCollection 2018 Jan 12. PMID: 29435104; PMCID: PMC5796975.
Copy Download .nbib Format: NLM
Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen.

OncoTargets and therapy

Xiao X, Ye X, Xu C, Huang J.
PMID: 30464503
Onco Targets Ther. 2018 Oct 29;11:7555-7558. doi: 10.2147/OTT.S177503. eCollection 2018.

OBJECTIVE: Acute lymphoblastic leukemia (ALL) is a malignant disease characterized by the accumulation of lymphoblasts, and a poor prognosis for adults with ALL is closely associated with disease recurrence. Thus far, treatment approaches have been limited, particularly in patients...

Cite
Xiao X, Ye X, Xu C, et al. Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen. Onco Targets Ther. 2018;11:7555-7558doi: 10.2147/OTT.S177503.
Xiao, X., Ye, X., Xu, C., & Huang, J. (2018). Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen. OncoTargets and therapy, 117555-7558. https://doi.org/10.2147/OTT.S177503
Xiao, XiaoFang, et al. "Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen." OncoTargets and therapy vol. 11 (2018): 7555-7558. doi: https://doi.org/10.2147/OTT.S177503
Xiao X, Ye X, Xu C, Huang J. Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen. Onco Targets Ther. 2018 Oct 29;11:7555-7558. doi: 10.2147/OTT.S177503. eCollection 2018. PMID: 30464503; PMCID: PMC6214580.
Copy Download .nbib Format: NLM
Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy.

Bioactive materials

Lian H, Meng Z.
PMID: 29744416
Bioact Mater. 2017 Apr 06;2(2):96-100. doi: 10.1016/j.bioactmat.2017.03.003. eCollection 2017 Jun.

Daunorubicin hydrochloride is a cell-cycle non-specific antitumor drug with a high therapeutic effect. The present study outlines the fabrication of daunorubicin hydrochloride-loaded poly (ε-caprolactone) (PCL) fibrous membranes by melt electrospinning for potential application in localized tumor therapy. The diameters...

Cite
Lian H, Meng Z. Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy. Bioact Mater. 2017;2(2):96-100doi: 10.1016/j.bioactmat.2017.03.003.
Lian, H., & Meng, Z. (2017). Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy. Bioactive materials, 2(2), 96-100. https://doi.org/10.1016/j.bioactmat.2017.03.003
Lian, He, and Meng, Zhaoxu. "Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy." Bioactive materials vol. 2,2 (2017): 96-100. doi: https://doi.org/10.1016/j.bioactmat.2017.03.003
Lian H, Meng Z. Melt electrospinning of daunorubicin hydrochloride-loaded poly (ε-caprolactone) fibrous membrane for tumor therapy. Bioact Mater. 2017 Apr 06;2(2):96-100. doi: 10.1016/j.bioactmat.2017.03.003. eCollection 2017 Jun. PMID: 29744416; PMCID: PMC5935042.
Copy Download .nbib Format: NLM
Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases.

Hematology reports

Vanegas YAM, Azzouqa AM, Menke DM, Foran JM, Vishnu P.
PMID: 30283621
Hematol Rep. 2018 Sep 05;10(3):7658. doi: 10.4081/hr.2018.7658. eCollection 2018 Sep 05.

Concurrent presentation of acute promyelocytic leukemia (APL) with other hematologic diseases in the absence of previous chemotherapy or ionizing radiotherapy treatment is very rare. We present a case of simultaneous occurrence of APL with myelodysplastic syndrome (MDS)-related acute myeloid...

Cite
Vanegas YAM, Azzouqa AM, Menke DM, et al. Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. Hematol Rep. 2018;10(3):7658doi: 10.4081/hr.2018.7658.
Vanegas, Y. A. M., Azzouqa, A. M., Menke, D. M., Foran, J. M., & Vishnu, P. (2018). Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. Hematology reports, 10(3), 7658. https://doi.org/10.4081/hr.2018.7658
Vanegas, Yenny Alejandra Moreno, et al. "Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases." Hematology reports vol. 10,3 (2018): 7658. doi: https://doi.org/10.4081/hr.2018.7658
Vanegas YAM, Azzouqa AM, Menke DM, Foran JM, Vishnu P. Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases. Hematol Rep. 2018 Sep 05;10(3):7658. doi: 10.4081/hr.2018.7658. eCollection 2018 Sep 05. PMID: 30283621; PMCID: PMC6151345.
Copy Download .nbib Format: NLM
Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.

Oncotarget

Fänder J, Kielstein H, Büttner M, Koelblinger P, Dummer R, Bauer M, Handke D, Wickenhauser C, Seliger B, Jasinski-Bergner S.
PMID: 31741714
Oncotarget. 2019 Nov 05;10(60):6509-6525. doi: 10.18632/oncotarget.27305. eCollection 2019 Nov 05.

The multistructural and multifunctional transmembrane glycoprotein CD44 is overexpressed in many tumors of distinct origin including malignant melanoma and contributes to a poor prognosis by affecting cell proliferation, cell migration, and also the sensitivity for apoptosis induction. Previous studies...

Cite
Fänder J, Kielstein H, Büttner M, et al. Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget. 2019;10(60):6509-6525doi: 10.18632/oncotarget.27305.
Fänder, J., Kielstein, H., Büttner, M., Koelblinger, P., Dummer, R., Bauer, M., Handke, D., Wickenhauser, C., Seliger, B., & Jasinski-Bergner, S. (2019). Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget, 10(60), 6509-6525. https://doi.org/10.18632/oncotarget.27305
Fänder, Johannes, et al. "Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma." Oncotarget vol. 10,60 (2019): 6509-6525. doi: https://doi.org/10.18632/oncotarget.27305
Fänder J, Kielstein H, Büttner M, Koelblinger P, Dummer R, Bauer M, Handke D, Wickenhauser C, Seliger B, Jasinski-Bergner S. Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma. Oncotarget. 2019 Nov 05;10(60):6509-6525. doi: 10.18632/oncotarget.27305. eCollection 2019 Nov 05. PMID: 31741714; PMCID: PMC6849650.
Copy Download .nbib Format: NLM
The Time Has Come for Targeted Therapies for AML: Lights and Shadows.

Oncology and therapy

Fiorentini A, Capelli D, Saraceni F, Menotti D, Poloni A, Olivieri A.
PMID: 32700072
Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24.

Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes,...

Cite
Fiorentini A, Capelli D, Saraceni F, et al. The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncol Ther. 2020;8(1):13-32doi: 10.1007/s40487-019-00108-x.
Fiorentini, A., Capelli, D., Saraceni, F., Menotti, D., Poloni, A., & Olivieri, A. (2020). The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncology and therapy, 8(1), 13-32. https://doi.org/10.1007/s40487-019-00108-x
Fiorentini, Alessandro, et al. "The Time Has Come for Targeted Therapies for AML: Lights and Shadows." Oncology and therapy vol. 8,1 (2020): 13-32. doi: https://doi.org/10.1007/s40487-019-00108-x
Fiorentini A, Capelli D, Saraceni F, Menotti D, Poloni A, Olivieri A. The Time Has Come for Targeted Therapies for AML: Lights and Shadows. Oncol Ther. 2020 Jun;8(1):13-32. doi: 10.1007/s40487-019-00108-x. Epub 2020 Jan 24. PMID: 32700072; PMCID: PMC7359996.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 337 entries